Aptose Reports First Quarter 2026 Results
View original at globenewswire.com“Cash and restricted cash $4,096 [thousand] as of December 31, 2025”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
TUS+VEN+AZA triplet is being developed as a safe and mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients ineligible to receive induction chemotherapy
60% confidenceThe expected acquisition of Aptose by Hanmi Pharmaceutical will allow continued development of tuspetinib for AML patients, including those with TP53-mutated disease
60% confidenceAptose is actively deploying cost reduction efforts to extend cash runway
60% confidenceThe first two dose cohorts at 40mg and 80mg of TUS in the TUS+VEN+AZA triplet demonstrated safety, complete remissions, and MRD negativity across patients with diverse mutations including TP53-mutated/CK AML and FLT3-wildtype AML
60% confidenceAptose does not have sufficient cash to fund operations and relies on advances made by Hanmi to fund operations
60% confidenceParties do not anticipate that Korean regulatory reviews will prevent the closing of the Hanmi acquisition arrangement
60% confidenceTUSCANY clinical trial of tuspetinib in combination with venetoclax and azacitidine continues to deliver robust safety and response data
60% confidence